PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Asthma

Drugs in development · updated 30 October 2026

Asthma: drugs in development

As of 30 October 2026 there are 96 active clinical trials (recruiting or ongoing, phases I–III) on 84 drugs for asthma. 51 are experimental, that is not yet approved in the United States.

96Active trials
51Experimental drugs
14Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
GSK5784283III4NCT07782996
GB-0895III3NCT07276724
TilrekimigPF-07275315III3NCT07772921
HFA-134aIII2NCT07645248
HFA-152aIII2NCT07645248
AcarizaxIII1NCT07013123
Dexpramipexole DihydrochlorideIII1NCT05748600
EpiCeramIII1NCT03667651
MG-K10III1NCT06837922
QMF149III1NCT05562466
QVM149III1NCT05776927
SHR-1905III1NCT07098403
TEV-56248III1NCT06052267
TQC2731III1NCT06829784
LunsekimigII2NCT06676319
PA9159II2NCT07326995
AK139II1NCT07436221
BrenipatideII1NCT07219173
CM512II1NCT07011524
CXA-10II1NCT03762395
ENV-294II1NCT07301255
ETH47II1NCT07059767
FrevecitinibII1NCT07532265
Ginger ExtractII1NCT07792395
HB0056I–II1NCT07899996
HSK31858II1NCT06637254
JNJ-95597528II1NCT07746687
KT-621II1NCT07677059
L-citrullineII1NCT05259904
LinvemastatII1NCT07191535
LQ036II1NCT07589439
PovorcitinibPovofortay®II1NCT05851443
PRA-216I–II1NCT07245368
RademikibartII1NCT07705737
SHR4597II1NCT06940700
TozorakimabII1NCT06932263
VerekitugII1NCT06966479
WIN378II1NCT07120503
Xenon-129II1NCT02740868
AMG 691I2NCT06637371

Sorted by most advanced phase and number of active trials. Showing 40 of 51 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
FormoterolPerforomist®, Foradil Certihaler®III6NCT07768891
BudesonideTarpeyo®, Eohilia®III5NCT05562466
TezepelumabTezspireIII5NCT06023589
DupilumabDUPIXENTIII4NCT07309614
BenralizumabFasenra®III3NCT05692180
DepemokimabExdensur®III3NCT07671001
UmeclidiniumUMEC, Incruse Ellipta®III3NCT05757102
Albuterol SulfateSalbutamol, Proair Respiclick®III2NCT06052267
Beclomethasone DipropionateBeclometasone Dipropionate, Qvar Redihaler®III2NCT07768891
Fluticasone PropionateFluticasone, Xhance®III2NCT05776927
DeflazacortEmflaza®II–III1NCT04227483
LevofloxacinLevaquin®, Iquix®II–III1NCT06859450
PrednisolonePrednisolon, PrenisoloneII–III1NCT04227483
Salmeterol XinafoateSerevent®III1NCT05776927
AmitriptylineElavil®II1NCT05110144

Sorted by most advanced phase and number of active trials. Showing 15 of 33 drugs.

All 84 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001249 “Asthma”.

ItalianoFrançaisDeutsch